Search

El angiomiolipoma (AML) es una neoplasia clonal benigna compuesta por cantidades variables de tejido adiposo maduro, músculo liso y vasos sanguíneos de paredes gruesas. Aproximadamente un 20% de todos los AML, se detectan en pacientes con el Síndrome de la Esclerosis Tuberosa, trastorno autonómico dominante que se asocia a retraso mental, epilepsia, adenoma sebáceo. La presencia de hemorragia retroperitoneal masiva, conocida como Síndrome de Wunderlich se ha documentado en hasta un 10% de los pacientes y representa la complicación más importante y temida de estas lesiones. La TAC identifica las zonas del tejido adiposo, correspondiente a una baja atenuación entre 20-100 Hounsfield, dicho coeficiente dependerá del contenido y madurez de la grasa intratumoral y de la presencia o no de hemorragias. En el caso de pacientes con AML pequeños que requieren intervención debido a la presencia de síntomas, en pacientes con ET o AML multicéntricos y en pacientes en quienes la preservación de la función renal reviste particular importancia el enfoque preferido es la cirugía ahorradora de nefronas con nefrectomía parcial o embolizaciòn selectiva. Presentamos un caso de una paciente de 59 años con un angiomiolipoma gigante quién debuta con el Síndrome clínico conocido como Tríada de Lenk.

OBJECTIVE: To assess the recently proposed preliminary criteria for the classification of Sjogren9s syndrome (SS) in a multicentre European study of a new series of clinically defined cases. METHODS: The criteria included six items: I = ocular symptoms; II = oral symptoms; III = evidence of keratoconjunctivitis sicca; IV = focal sialoadenitis by minor salivary gland biopsy; V = instrumental evidence of salivary gland involvement; VI = presence of autoantibodies. Each centre was asked to provide five patients with primary SS, five with secondary SS, five with connective tissue diseases (CTD) but without SS, and five controls (patients with ocular or oral features that may simulate SS). The preliminary six item classification criteria set was applied to both the SS patients and the non-SS controls, and the performance of the criteria in terms of sensitivity and specificity was tested. RESULTS: The criteria set was tested on a total of 278 cases (157 SS patients and 121 non-SS controls) collected from 16 centres in 10 countries. At least four of the six items in the criteria set (limiting item VI to the presence of Ro(SS-A) or La(SS-B) antibodies) were present in 79 of 81 patients initially classified as having primary SS (sensitivity 97.5%), but in only seven of 121 non-SS controls (specificity 94.2%). When the presence of item I or II plus any two of items III-V of the criteria set was considered as indicative of secondary SS, 97.3% (71 of 73) of the patients initially defined as having this disorder and 91.8% (45 of 49) of the control patients with CTD without SS were correctly classified. CONCLUSION: This prospective study confirmed the high validity and reliability of the classification criteria for SS recently proposed by the European Community Study Group.